HRP20040112B1 - Crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof - Google Patents

Crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Info

Publication number
HRP20040112B1
HRP20040112B1 HR20040112A HRP20040112A HRP20040112B1 HR P20040112 B1 HRP20040112 B1 HR P20040112B1 HR 20040112 A HR20040112 A HR 20040112A HR P20040112 A HRP20040112 A HR P20040112A HR P20040112 B1 HRP20040112 B1 HR P20040112B1
Authority
HR
Croatia
Prior art keywords
acid salt
ylidene
carboxamide
diethylamino
indole
Prior art date
Application number
HR20040112A
Other languages
English (en)
Croatian (hr)
Inventor
Hawley Michael
J. Fleck Thomas
P. Prescott Stephen
T. Maloney Mark
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20040112(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of HRP20040112A2 publication Critical patent/HRP20040112A2/hr
Publication of HRP20040112B1 publication Critical patent/HRP20040112B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
HR20040112A 2001-08-15 2002-08-13 Crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof HRP20040112B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15
PCT/US2002/025649 WO2003016305A1 (en) 2001-08-15 2002-08-13 Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Publications (2)

Publication Number Publication Date
HRP20040112A2 HRP20040112A2 (en) 2004-06-30
HRP20040112B1 true HRP20040112B1 (en) 2012-03-31

Family

ID=23211067

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040112A HRP20040112B1 (en) 2001-08-15 2002-08-13 Crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Country Status (42)

Country Link
US (2) US20030069298A1 (enExample)
EP (3) EP2332934B1 (enExample)
JP (1) JP4159988B2 (enExample)
KR (1) KR100639281B1 (enExample)
CN (2) CN100364991C (enExample)
AP (1) AP1660A (enExample)
AR (1) AR036261A1 (enExample)
AU (1) AU2002324684B2 (enExample)
BG (1) BG108553A (enExample)
BR (1) BR0211612A (enExample)
CA (1) CA2455050C (enExample)
CO (1) CO5550431A2 (enExample)
CU (1) CU23713B7 (enExample)
CY (1) CY1121552T1 (enExample)
CZ (1) CZ2004196A3 (enExample)
DK (2) DK1419151T3 (enExample)
EA (1) EA006445B9 (enExample)
EC (1) ECSP044975A (enExample)
ES (3) ES2623094T3 (enExample)
GE (1) GEP20063777B (enExample)
HR (1) HRP20040112B1 (enExample)
HU (1) HU229206B1 (enExample)
IL (1) IL160097A0 (enExample)
IS (1) IS7147A (enExample)
MA (1) MA27058A1 (enExample)
ME (1) ME00414B (enExample)
MX (1) MXPA04001452A (enExample)
MY (1) MY139383A (enExample)
NO (1) NO326508B1 (enExample)
NZ (1) NZ531232A (enExample)
OA (1) OA12650A (enExample)
PL (1) PL216524B1 (enExample)
PT (2) PT3168218T (enExample)
RS (1) RS53251B (enExample)
SI (2) SI1419151T1 (enExample)
SK (1) SK902004A3 (enExample)
TN (1) TNSN04028A1 (enExample)
TR (1) TR201900509T4 (enExample)
TW (1) TWI269796B (enExample)
UA (1) UA76483C2 (enExample)
WO (1) WO2003016305A1 (enExample)
ZA (1) ZA200400706B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2004196A3 (cs) 2001-08-15 2005-01-12 Pharmacia & Upjohn Company Krystaly obsahující sůl N-[2-(diethylamino)ethyl]-5-[(5-fluor-2-oxo-3H-indol-3-yliden) methyl]-2,4-dimethyl-1H-pyrrol 3-karboxamidu s kyselinou jablečnou, způsob jejich výroby a kompozice na jejich bázi
TW200418836A (en) * 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
PT1670785E (pt) * 2003-10-02 2010-09-16 Pharmacia & Upjohn Co Llc Sais e polimorfos de um composto de indolinona substituída com pirrole
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
MX2007000892A (es) * 2004-07-22 2007-05-23 Lilly Co Eli Un hidrato variable cristalino de la sal de (s)-3-piridincarboxami da, 6-[4-[2-[[3-(9h-carbazol-4-iloxi)-2-hidroxipropil]amino]-2-met ilpropil]fenoxi]-hemisuccinato.
WO2006120557A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
CA2621569C (en) 2005-09-19 2010-10-19 Pfizer Products Inc. Solid salt forms of a pyrrole substituted 2-indolinone
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
EP2220071A2 (en) * 2007-11-21 2010-08-25 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
US8389562B2 (en) * 2007-12-12 2013-03-05 Medichem, S.A. Polymorphic forms of a 3-pyrrole substituted 2-indolinone
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
AU2009215377A1 (en) * 2008-02-21 2009-08-27 Generics [Uk] Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
CA2720164A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
EP2280960A1 (en) * 2008-04-16 2011-02-09 Natco Pharma Limited Novel polymorphic forms of sunitinib base
US8829039B2 (en) 2008-05-23 2014-09-09 Shanghai Institute Of Pharmaceutical Industry Dihydroindolinone derivatives
WO2009150523A1 (en) * 2008-06-13 2009-12-17 Medichem, S.A. Process for preparing a 3-pyrrole substituted 2-indolinone malate salt
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
WO2010004339A1 (en) 2008-07-10 2010-01-14 Generics [Uk] Limited Processes for the preparation of crystalline forms of sunitinib malate
WO2010011834A2 (en) * 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
CN102164913A (zh) * 2008-07-24 2011-08-24 麦迪凯姆股份公司 一种3-吡咯替代的2-吲哚酮苹果酸盐的结晶体形式
CN102197035A (zh) * 2008-08-25 2011-09-21 基因里克斯(英国)有限公司 舒尼替尼的结晶形式及其制备方法
JP2012500838A (ja) * 2008-08-25 2012-01-12 ジェネリクス・（ユーケー）・リミテッド スニチニブの新規な多形およびその調製方法
EP2350056A1 (en) * 2008-10-10 2011-08-03 Medichem, S.A. Process for preparing a 3-pyrrole subsituted 2-indolinone malate salt
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2373643A4 (en) * 2009-01-02 2013-08-07 Hetero Research Foundation NEW SUNITINIB MALATE POLYMORPHS
DK2387563T4 (da) 2009-01-16 2022-07-18 Exelixis Inc Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
AU2010296849A1 (en) 2009-09-16 2012-05-03 Ranbaxy Laboratories Limited Salts of sunitinib
EP2499133A2 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
EP2501694A1 (en) 2009-11-19 2012-09-26 Ranbaxy Laboratories Limited Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib
CA2788709A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
US20130123511A1 (en) 2010-03-04 2013-05-16 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
WO2011114246A1 (en) 2010-03-18 2011-09-22 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CA3019531A1 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
EP2828251B1 (en) 2012-03-23 2018-10-31 Laurus Labs Limited An improved process for the preparation of sunitinib and its acid addition salts thereof
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
US9604968B2 (en) 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
CA2838585A1 (en) 2013-10-18 2015-04-18 Hari Babu Matta An ascorbic acid salt of sunitinib
KR102196884B1 (ko) 2013-11-01 2020-12-30 화이자 인코포레이티드 전립선-연관 항원의 발현을 위한 벡터
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
JP2022529290A (ja) * 2019-04-18 2022-06-20 メーター ヘルス インコーポレイテッド 呼吸性不整脈を処置するための方法および組成物
EP3958845A1 (en) 2019-04-25 2022-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
JP7633786B2 (ja) * 2020-09-18 2025-02-20 日本化薬株式会社 スニチニブリンゴ酸塩を有効成分とする医薬錠剤
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037820A2 (en) * 1999-11-24 2001-05-31 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands
WO2001060814A2 (en) * 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9190141U1 (de) 1990-10-15 1993-07-15 Pfizer Inc., New York, N.Y. Indolderivate
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
CZ282060B6 (cs) 1992-06-05 1997-05-14 Merck Sharp And Dohme Limited Sulfátová sůl substituovaného triazolu, způsob její výroby, farmaceutický prostředek s jejím obsahem a způsob jeho výroby
HU222244B1 (hu) 1993-03-12 2003-05-28 Pharmacia & Upjohn Co. Szabad sav formájában lévő kristályos ceftiofur, ennek előállítása és ezt tartalmazó gyógyászati készítmény
US6329364B1 (en) 1994-08-31 2001-12-11 Eli Lilly And Company Crystalline form of dihydro-2,3-benzodiazepine derivative
DE19503966C2 (de) 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020038021A1 (en) 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en) 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US6066647A (en) 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
CN1205193C (zh) * 1996-08-14 2005-06-08 G·D·瑟尔公司 4－[5－甲基－3－苯基异噁唑－4－基]苯磺酰胺的晶型
WO1998029344A1 (fr) 1996-12-25 1998-07-09 Nippon Kayaku Kabushiki Kaisha Poudre de cisplatine fine et son procede de production
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
BR9906539A (pt) 1998-06-19 2000-08-15 Teijin Ltd Polimorfo de ácido 2-(3-ciano-4-isobutil-óxi-fenil)-4-metil-5-tiazol-carboxì lico, composto amorfo, processos para produção de um composto amorfo, para produção de cristal, a, b, c, d, g de ácido. 2-(3-ciano-4-isobutil-óxi-fenil)-4-metil-5-tiazol-carboxì lico, e, polimorfo
EP1157019B1 (en) * 1998-12-17 2003-03-19 F. Hoffmann-La Roche Ag 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
CZ2004196A3 (cs) 2001-08-15 2005-01-12 Pharmacia & Upjohn Company Krystaly obsahující sůl N-[2-(diethylamino)ethyl]-5-[(5-fluor-2-oxo-3H-indol-3-yliden) methyl]-2,4-dimethyl-1H-pyrrol 3-karboxamidu s kyselinou jablečnou, způsob jejich výroby a kompozice na jejich bázi
AU2009215377A1 (en) 2008-02-21 2009-08-27 Generics [Uk] Limited Novel polymorphs and processes for their preparation
WO2009156837A2 (en) 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037820A2 (en) * 1999-11-24 2001-05-31 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands
WO2001060814A2 (en) * 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors

Also Published As

Publication number Publication date
NO326508B1 (no) 2008-12-15
NO20041054L (no) 2004-03-12
HUP0700036A2 (en) 2008-10-28
US20070191458A1 (en) 2007-08-16
BR0211612A (pt) 2004-08-24
ES2453164T3 (es) 2014-04-04
EA006445B1 (ru) 2005-12-29
SK902004A3 (sk) 2005-03-04
EP3168218B1 (en) 2018-11-14
CN1543462A (zh) 2004-11-03
EP2332934B1 (en) 2017-03-01
TNSN04028A1 (fr) 2006-06-01
TWI269796B (en) 2007-01-01
ES2623094T3 (es) 2017-07-10
US7435832B2 (en) 2008-10-14
WO2003016305A1 (en) 2003-02-27
CN100364991C (zh) 2008-01-30
PL216524B1 (pl) 2014-04-30
OA12650A (en) 2006-06-19
PT3168218T (pt) 2019-01-11
CO5550431A2 (es) 2005-08-31
EP2332934A1 (en) 2011-06-15
SI3168218T1 (sl) 2019-05-31
EA006445B9 (ru) 2017-02-28
EA200400183A1 (ru) 2004-08-26
IS7147A (is) 2004-02-10
PL368317A1 (en) 2005-03-21
SI1419151T1 (sl) 2014-04-30
MXPA04001452A (es) 2004-05-20
US20030069298A1 (en) 2003-04-10
KR100639281B1 (ko) 2006-10-31
EP1419151A1 (en) 2004-05-19
HK1088008A1 (zh) 2006-10-27
JP4159988B2 (ja) 2008-10-01
EP1419151B1 (en) 2014-02-26
CN1789264A (zh) 2006-06-21
CZ2004196A3 (cs) 2005-01-12
EP3168218A1 (en) 2017-05-17
RS53251B (sr) 2014-08-29
UA76483C2 (en) 2006-08-15
KR20040030074A (ko) 2004-04-08
ME00414B (me) 2011-10-10
HK1066542A1 (en) 2005-03-24
CN100439360C (zh) 2008-12-03
MA27058A1 (fr) 2004-12-20
CU20040029A7 (es) 2008-03-14
HRP20040112A2 (en) 2004-06-30
NZ531232A (en) 2004-11-26
CU23713B7 (es) 2011-10-05
DK3168218T3 (en) 2019-01-14
TR201900509T4 (tr) 2019-02-21
RS10304A (sr) 2007-02-05
AU2002324684B2 (en) 2006-10-05
AP2004002976A0 (en) 2004-03-31
IL160097A0 (en) 2004-06-20
ECSP044975A (es) 2004-03-23
GEP20063777B (en) 2006-03-27
DK1419151T3 (da) 2014-03-31
ZA200400706B (en) 2005-05-25
BG108553A (bg) 2005-04-30
PT1419151E (pt) 2014-03-27
CA2455050C (en) 2007-02-20
AR036261A1 (es) 2004-08-25
ES2705063T3 (es) 2019-03-21
CY1121552T1 (el) 2020-05-29
AP1660A (en) 2006-09-09
CA2455050A1 (en) 2003-02-27
JP2005503386A (ja) 2005-02-03
HU229206B1 (en) 2013-09-30
MY139383A (en) 2009-09-30

Similar Documents

Publication Publication Date Title
HRP20040112B1 (en) Crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
DK1470114T3 (da) Peptid-nukleinsyre-oligomerer fra 1-benzensulfonyl-3-aminosyre sidekæde-4-(2-nucleobase(acetyl))-piperazin-2-oner
NO20091892L (no) Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
ATE374765T1 (de) Substituierte heterocyclische amide
BR0307060A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
NO20050832L (no) Selektive estrogenreseptormodulatorer inneholdende en fenylsulonylgruppe
HU0100973D0 (en) Use of heteroaryl substituted n-(indole-2-carbonyl)-amide derivatives for the treatment of infections
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
ATE455761T1 (de) Neue atorvastatinsalze und pharmazeutische zusammensetzungen, die diese enthalten
ATE240098T1 (de) Stoffe zur hemmung der bildung des pterygiums und seines postoperative wiederauftretens
ATE280776T1 (de) Medizinische verwendung von mechanismus- orientierten inhibitoren der dipeptidylpeptidase i
DE60110233D1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
DK1584617T3 (da) Alkylpyridiniumdicyanamider som polære opløsningsmidler
WO2001030759A3 (en) Sodium-hydrogen exchanger type 1 inhibitor crystals
NO20031030D0 (no) Nye krystaller av N-hydroksy-2(S)-metyl-5-etoksymetoksy-4(S)- [N-(4-fenoksyfenylkarbonyl)amino]pentanamid, fremgangsmåte for deresfremstilling og medisinerinneholdende krystallene som den aktive bestanddel
TH66471A (th) N-ยูรีอิโดแอลคิล-พิเพอริดีนในฐานะสารปรับแอคติวิตีของคีโมไคน์รีเซปเตอร์
DE602004016331D1 (de) Pentafluoroalkylsulfin-naphthaline und und darauf bezogene modulatoren des östrogenrezeptors
TH69655A (th) ผลึกซึ่งประกอบด้วยเกลือของกรดมาลิคของ 3-ไพร์รอล ซับสทิทิวเทด 2-อินโดลิโนน และสารผสมของสารเหล่านี้
DK1105388T3 (da) N-substituerede azabicycloheptan-derivater, fremstilling og anvendelse heraf
RU99109460A (ru) Пиразолиноны для лечения нарушения потенции

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190807

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200730

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210811

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20220813